Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TCJL37, a potent, selective, and orally bioavailable inhibitor of TYK2, exhibits a K i value of 1.6 nM. It is useful for researching inflammatory bowel diseases (IBD) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | 35 days | $ 543.00 |
Description | TCJL37, a potent, selective, and orally bioavailable inhibitor of TYK2, exhibits a K i value of 1.6 nM. It is useful for researching inflammatory bowel diseases (IBD) [1]. |
In vitro | In cell-based assays, TCJL37 (Compound 37) exhibits IL-12 pSTAT4 EC 50 of 224 nM. TCJL37 exhibits EC 50 s of 168 nM and 737 nM In human peripheral blood mononuclear cells (PBMC) and human whole blood assay, respectively [1]. |
In vivo | TCJL37 shows high oral bioavailability in CD-1 mice when administered orally at a dosage of 100 mg/kg. Additionally, TCJL37 exhibits low metabolic clearance, measured at 1.0 mL/min/kg, in rats [1]. |
Molecular Weight | 376.74 |
Formula | C17H11ClF2N4O2 |
CAS No. | 1258294-34-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TCJL37 1258294-34-6 Compound T 4666 Compound T-4666 Compound T4666 inhibitor inhibit